Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009

Yok‐Lam Kwong(Queen Mary Hospital), Soon-Thye Lim(National Cancer Centre Singapore), Ranjana H. Advani(Stanford Medicine), Benjamin O. Anderson(University of Washington), Alexandra M. Levine(City of Hope), Won-Seog Kim(Samsung Medical Center)

The Lancet Oncology

October 30, 2009

10.1016/s1470-2045(09)70265-7

Cited by 120

Related Papers

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition

|The Lancet|2015|2k

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

|Journal of the National Comprehensive Cancer Network|2018|1.6k

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

|Blood|2022|1.5k

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

|Journal of Clinical Oncology|2012|1.1k

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

|Nature Medicine|2015|1.1k